MA43529A - Modulateurs de transport nucléaire et leurs utilisations - Google Patents
Modulateurs de transport nucléaire et leurs utilisationsInfo
- Publication number
- MA43529A MA43529A MA043529A MA43529A MA43529A MA 43529 A MA43529 A MA 43529A MA 043529 A MA043529 A MA 043529A MA 43529 A MA43529 A MA 43529A MA 43529 A MA43529 A MA 43529A
- Authority
- MA
- Morocco
- Prior art keywords
- nuclear transport
- transport modulators
- modulators
- nuclear
- transport
- Prior art date
Links
- 230000025308 nuclear transport Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562273857P | 2015-12-31 | 2015-12-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43529A true MA43529A (fr) | 2018-11-07 |
Family
ID=57799957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA043529A MA43529A (fr) | 2015-12-31 | 2016-12-30 | Modulateurs de transport nucléaire et leurs utilisations |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10526295B2 (fr) |
| EP (1) | EP3397633A1 (fr) |
| MA (1) | MA43529A (fr) |
| WO (1) | WO2017117529A1 (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4234545A3 (fr) | 2011-07-29 | 2023-09-06 | Karyopharm Therapeutics Inc. | Modulateurs de transport nucléaire contenant de l'hydrazide et leurs utilisations |
| WO2013170068A2 (fr) | 2012-05-09 | 2013-11-14 | Karyopharm Therapeutics, Inc. | Modulateurs du transport nucléaire et leurs utilisations |
| EP2968278B8 (fr) | 2013-03-15 | 2019-05-22 | Karyopharm Therapeutics Inc. | Procédés de promotion de la cicatrisation d'une plaie à l'aide d'inhibiteurs de crm1 |
| ME03421B (fr) | 2013-06-21 | 2020-01-20 | Karyopharm Therapeutics Inc | 1,2,4-triazoles en tant que modulateurs de transport nucléaire et leurs utilisations |
| KR102608259B1 (ko) | 2014-08-15 | 2023-11-29 | 카리오팜 쎄라퓨틱스, 인코포레이티드 | 셀리넥소의 다형태 |
| US10526295B2 (en) | 2015-12-31 | 2020-01-07 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| EP3397634A1 (fr) * | 2015-12-31 | 2018-11-07 | Karyopharm Therapeutics, Inc. | Modulateurs de transport nucléaire et leurs utilisations |
| US11602530B2 (en) | 2016-11-28 | 2023-03-14 | Biogen Ma Inc. | CRM1 inhibitors for treating epilepsy |
| PL3737665T3 (pl) | 2018-01-10 | 2026-04-20 | XWPharma Ltd. | Proleki ketaminy, ich kompozycje i zastosowania |
| WO2019232724A1 (fr) * | 2018-06-06 | 2019-12-12 | Xw Laboratories, Inc. | Composés en tant que modulateurs de transport nucléaire et leurs utilisations |
| CN114040909B (zh) | 2019-05-01 | 2025-06-03 | 卡尔约药物治疗公司 | 用于制备xpo1抑制剂以及用于制备xp01抑制剂的中间体的方法 |
| WO2021247447A1 (fr) * | 2020-06-01 | 2021-12-09 | Luke Klele | Compositions antivirales |
| WO2022089629A1 (fr) * | 2020-11-02 | 2022-05-05 | 江苏柯菲平医药股份有限公司 | Dérivé de 1,2,4-triazole, son procédé de préparation et son utilisation |
| KR20240012445A (ko) * | 2021-05-20 | 2024-01-29 | 카리오팜 쎄라퓨틱스, 인코포레이티드 | 트리아졸릴 아크릴아미드의 헤테로아릴 유도체 및 결정질 형태의 합성 방법 |
| EP4559522A3 (fr) | 2021-08-13 | 2025-07-16 | XWPharma Ltd. | Compositions pharmaceutiques et formes posologiques orales de dérivés de kétamine |
| WO2023036217A1 (fr) * | 2021-09-08 | 2023-03-16 | 南京明德新药研发有限公司 | Composé d'acrylamide et son utilisation |
| CA3235436A1 (fr) * | 2021-10-29 | 2023-05-04 | Fei Liu | Compose contenant du pyridyle |
| CN119053594A (zh) * | 2022-01-12 | 2024-11-29 | 上海海雁医药科技有限公司 | 核转运调节剂及其用途 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1017398A (en) | 1911-01-16 | 1912-02-13 | John E Folsom | Telegraph-key. |
| KR840000529A (ko) | 1981-07-07 | 1984-02-25 | 콘스탄틴 루이스 클레멘트 | 인돌 유도체의 제조방법 |
| CS229934B2 (en) | 1981-07-07 | 1984-07-16 | Pfizer | Production method subst.indolylacryte acid derivative |
| US4778796A (en) | 1985-07-19 | 1988-10-18 | Dainippon Pharmaceutical Co., Ltd. | ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same |
| JP3111321B2 (ja) | 1990-02-23 | 2000-11-20 | 武田薬品工業株式会社 | 縮合チアゾール化合物 |
| IL97249A (en) | 1990-02-23 | 1995-01-24 | Takeda Chemical Industries Ltd | Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or |
| US5541213A (en) | 1993-06-24 | 1996-07-30 | Eisai Co., Ltd. | Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility |
| EP0793653A1 (fr) | 1994-11-23 | 1997-09-10 | Neurogen Corporation | Certains derives 4-aminomethyl 2-substitues de l'imidazole et derives 2-aminomethyl 4-substitues de l'imidazole, nouvelles categories de ligands specifiques du sous-type du recepteur de la dopamine |
| US20030018025A1 (en) | 1995-06-07 | 2003-01-23 | Neurogen Corporation, Corporation Of The State Of Delaware | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands |
| JPH11513382A (ja) | 1995-10-20 | 1999-11-16 | ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング | ５員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法 |
| DE69736775T2 (de) | 1996-04-04 | 2007-08-23 | Shionogi & Co., Ltd. | Cephemverbindungen und medikamente die diese verbindungen enthalten |
| AU736854B2 (en) | 1996-04-25 | 2001-08-02 | Nissan Chemical Industries Ltd. | Ethylene derivatives and pesticides containing said derivatives |
| JP4054992B2 (ja) | 1996-04-25 | 2008-03-05 | 日産化学工業株式会社 | エチレン誘導体および有害生物防除剤 |
| DE19624659A1 (de) | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalken- und Pyridylalkinsäureamide |
| US5994398A (en) | 1996-12-11 | 1999-11-30 | Elan Pharmaceuticals, Inc. | Arylsulfonamides as phospholipase A2 inhibitors |
| JP4416198B2 (ja) | 1997-12-19 | 2010-02-17 | 武田薬品工業株式会社 | アニリド誘導体、その製造法および用途 |
| AU2960599A (en) | 1998-03-30 | 1999-10-18 | Akira Karasawa | Quinazoline derivatives |
| CO5271680A1 (es) | 2000-02-21 | 2003-04-30 | Smithkline Beecham Corp | Compuestos |
| EP1335898B1 (fr) | 2000-09-29 | 2005-11-23 | TopoTarget UK Limited | Composes d'acide carbamique comprenant un enchainement amide comme inhibiteurs hdac |
| CN101851173A (zh) | 2001-09-14 | 2010-10-06 | 梅特希尔基因公司 | 组蛋白脱乙酰化酶抑制剂 |
| AU2003287965A1 (en) | 2002-10-24 | 2004-05-13 | Carex Sa | Modulation of peroxisome proliferator activated receptors activity |
| DE10250743A1 (de) | 2002-10-31 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
| JP4145230B2 (ja) | 2002-11-01 | 2008-09-03 | 武田薬品工業株式会社 | 神経障害の予防・治療剤 |
| AU2003278600A1 (en) | 2002-11-01 | 2004-05-25 | Takeda Pharmaceutical Company Limited | Agent for preventing or treating neuropathy |
| AU2003291403A1 (en) | 2002-11-08 | 2004-06-03 | Neurogen Corporation | 3-substituted-6-aryl pyridined as ligands of c5a receptors |
| EP1599447A1 (fr) | 2003-02-28 | 2005-11-30 | Galderma Research & Development, S.N.C. | Ligands modulant des recepteurs du type lxr |
| RU2361872C2 (ru) | 2004-05-26 | 2009-07-20 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Циннамидное соединение |
| AU2005272389B2 (en) | 2004-08-11 | 2011-08-04 | Kyorin Pharmaceutical Co., Ltd. | Novel cyclic aminobenzoic acid derivative |
| WO2006019020A1 (fr) | 2004-08-16 | 2006-02-23 | Sankyo Company, Limited | Urées de substitution |
| WO2006088246A1 (fr) | 2005-02-18 | 2006-08-24 | Takeda Pharmaceutical Company Limited | Agent de controle de la fonction du recepteur gpr34 |
| PL1954684T3 (pl) | 2005-11-15 | 2014-10-31 | Otsuka Pharma Co Ltd | Związek oksazolowy i kompozycja farmaceutyczna |
| JP2007210929A (ja) | 2006-02-09 | 2007-08-23 | Sankyo Co Ltd | ウレア化合物を含有する医薬 |
| AR059955A1 (es) | 2006-03-09 | 2008-05-14 | Eisai R&D Man Co Ltd | Compuestos policiclicos no peptidicos, medicamentos que los contienen, y usos para prevenir o tratar enfermedades causadas por la produccion de beta amiloide |
| CN101466670B (zh) | 2006-04-07 | 2013-04-17 | 梅特希尔基因公司 | 组蛋白脱乙酰酶抑制剂 |
| CN101466687B (zh) | 2006-04-18 | 2012-04-11 | 日本化学医药株式会社 | 过氧化物酶体增殖剂激活受体δ的激活剂 |
| KR101130380B1 (ko) | 2006-06-13 | 2012-04-23 | 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 | 헤테로시클릭 비뉴클레오시드 화합물, 그의 제조방법, 약학적 조성물 및 항바이러스성 약제로서의 용도 |
| AU2007277519B2 (en) | 2006-07-27 | 2011-12-22 | Amorepacific Corporation | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same |
| TWI386405B (zh) | 2006-09-05 | 2013-02-21 | 咪唑衍生物 | |
| EP1939180A1 (fr) | 2006-12-20 | 2008-07-02 | sanofi-aventis | Hétéroarylacrylamides et leur utilisation en tant que médicament pour la stimulation de l'expression de la synthase NO endotheliale |
| EP1942104A1 (fr) | 2006-12-20 | 2008-07-09 | sanofi-aventis | Hétéroarylcyclopropanecarboxamide et leur utilisation pharmaceutique |
| WO2008106047A2 (fr) | 2007-02-26 | 2008-09-04 | Kosan Biosciences Incorporated | Composés de carbamate |
| EP2003118A1 (fr) | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Dérivés d'acides de cannelle en tant que modulateurs du récepteur EP2 |
| JP2012532889A (ja) | 2009-07-09 | 2012-12-20 | クレッシェンド セラピューティクス、エルエルシー | 創傷治療方法及び傷跡変性方法 |
| US8518968B2 (en) | 2009-12-04 | 2013-08-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hydrazone and diacyl hydrazine compounds and methods of use |
| EP2542089B1 (fr) | 2010-03-05 | 2017-01-18 | Karyopharm Therapeutics, Inc. | Modulateurs de transport nucléaire et leurs utilisations |
| EP2665362B1 (fr) | 2011-01-17 | 2016-03-30 | Karyopharm Therapeutics, Inc. | Modulateurs du transport nucléaire contenant des oléfines et leurs utilisations |
| EP4234545A3 (fr) | 2011-07-29 | 2023-09-06 | Karyopharm Therapeutics Inc. | Modulateurs de transport nucléaire contenant de l'hydrazide et leurs utilisations |
| JP6006794B2 (ja) | 2011-07-29 | 2016-10-12 | カリオファーム セラピューティクス，インコーポレイテッド | 核内輸送調節因子およびその使用 |
| WO2013020024A2 (fr) | 2011-08-03 | 2013-02-07 | Karyopharm Therapeutics, Inc. | Composés de maléimide et méthodes de traitement |
| WO2013170068A2 (fr) | 2012-05-09 | 2013-11-14 | Karyopharm Therapeutics, Inc. | Modulateurs du transport nucléaire et leurs utilisations |
| CN102777158B (zh) | 2012-07-06 | 2014-09-10 | 西南石油大学 | 测调联动系统及其操作工艺 |
| WO2014152263A1 (fr) | 2013-03-15 | 2014-09-25 | Karyopharm Therapeutics Inc. | Modulateurs de transport nucléaire contenant une exo-oléfine et leurs utilisations |
| EP2968278B8 (fr) | 2013-03-15 | 2019-05-22 | Karyopharm Therapeutics Inc. | Procédés de promotion de la cicatrisation d'une plaie à l'aide d'inhibiteurs de crm1 |
| ME03421B (fr) | 2013-06-21 | 2020-01-20 | Karyopharm Therapeutics Inc | 1,2,4-triazoles en tant que modulateurs de transport nucléaire et leurs utilisations |
| WO2014205393A1 (fr) | 2013-06-21 | 2014-12-24 | Karyopharm Therapeutics Inc. | Modulateurs de transport nucléaire et leurs utilisations |
| US11567063B2 (en) | 2013-11-15 | 2023-01-31 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Methods for assessing cell viability or predicting cell response to a treatment using cell movement |
| CN105294682B (zh) | 2014-07-26 | 2017-07-07 | 广东东阳光药业有限公司 | Cdk类小分子抑制剂的化合物及其用途 |
| KR102608259B1 (ko) | 2014-08-15 | 2023-11-29 | 카리오팜 쎄라퓨틱스, 인코포레이티드 | 셀리넥소의 다형태 |
| US10526295B2 (en) | 2015-12-31 | 2020-01-07 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| EP3397634A1 (fr) | 2015-12-31 | 2018-11-07 | Karyopharm Therapeutics, Inc. | Modulateurs de transport nucléaire et leurs utilisations |
| US11602530B2 (en) | 2016-11-28 | 2023-03-14 | Biogen Ma Inc. | CRM1 inhibitors for treating epilepsy |
-
2016
- 2016-12-30 US US16/066,554 patent/US10526295B2/en active Active
- 2016-12-30 WO PCT/US2016/069492 patent/WO2017117529A1/fr not_active Ceased
- 2016-12-30 EP EP16826682.3A patent/EP3397633A1/fr not_active Withdrawn
- 2016-12-30 MA MA043529A patent/MA43529A/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20190016690A1 (en) | 2019-01-17 |
| EP3397633A1 (fr) | 2018-11-07 |
| WO2017117529A1 (fr) | 2017-07-06 |
| US10526295B2 (en) | 2020-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43529A (fr) | Modulateurs de transport nucléaire et leurs utilisations | |
| FR24C1023I2 (fr) | Anticorps thérapeutiques et leurs utilisations | |
| MA50618A (fr) | Polyrhérapies et leurs utilisations | |
| EP3490565A4 (fr) | Modulateurs de récepteurs de chimiokine et leurs utilisations | |
| MA49537A (fr) | Anticorps anti-lag3 et leurs utilisations | |
| EP3523294A4 (fr) | Modulateurs de calpain et leurs utilisations thérapeutiques | |
| EP3328895A4 (fr) | Anticorps anti-pd-l1 et leurs utilisations | |
| MA43530A (fr) | Modulateurs de transport nucléaire et leurs utilisations | |
| EP3334706A4 (fr) | Pillararènes et utilisations de ceux-ci | |
| EP3344275A4 (fr) | Macrocycles peptidomimétiques et leurs utilisations | |
| MA46704A (fr) | Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations | |
| MA53145A (fr) | Agents de liaison cd123 et leurs utilisations | |
| MA42622A (fr) | Agents de liaison à tigit et leurs utilisations | |
| EP3283517A4 (fr) | Anticorps anti-pacap et leurs utilisations | |
| MA43567A (fr) | Anticorps pacap et leurs utilisations | |
| EP3349802A4 (fr) | Dendrimères lipocationiques et leurs utilisations | |
| EP3337486A4 (fr) | Composés deutérés et leurs utilisations | |
| EP3294318A4 (fr) | Macrocycles peptidomimétiques et leurs utilisations | |
| MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
| EP3364958A4 (fr) | Modulateurs d'interaction sestrine-gator2 et leurs utilisations | |
| EP3347021A4 (fr) | Cyano-thiénotriazoloazépines et leurs utilisations | |
| EP3538261A4 (fr) | Catalyseurs en pérovskite et leurs utilisations | |
| EP3347020A4 (fr) | Acétamide thiénotriazoldiazépines et leurs utilisations | |
| EP3341007A4 (fr) | Inhibiteurs de malt1 et leurs utilisations | |
| MA46901A (fr) | Agents psychotropes et leurs utilisations |